Travere Therapeutics prices $200M public offering of common stock and pre-funded warrants

Travere Therapeutics, Inc.

Offering of 8,275,000 shares at $21.00/share and 1,250,000 pre-funded warrants at $20.9999 each.
Gross proceeds ~$200M; net proceeds ~$187.6M after underwriting discounts and expenses.
Proceeds to support commercial launch of FILSPARI (sparsentan) for IgAN and potential FSGS launch.
Underwriters granted 30-day option to purchase up to 1,428,750 additional shares.
Closing expected March 3, 2023; Jefferies, J.P. Morgan, BofA Securities, SVB Securities as joint book-runners.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.